CORD BLOOD the focus of world-first clinical trial for treatment of COVID-19
Channel 7 News have reported cord blood-derived cells are being used in a world first clinical trial to treat COVID-19.
Monash University and Monash Health are undertaking the trial for severe COVID-19 patients who are anticipated to improve within 24 hours of cord blood treatment.
Key information:
- Umbilical cord derived cells will be expanded for adult doses
- Cord blood derived cells aim to significantly decrease the amount of oxygen needed by patients during hospital stays, and will accelerate recovery times
- Cord blood cells have anti-inflammatory and immunomodulatory properties that will impact respiratory disorders Covid-19 patients face
- 24 patients will take part in the Phase 1 trial
Click here to read more on 7news.